

For Immediate Release

Pasture Holdings Signs Term Sheet with the Thai Government for Distribution of its Proprietary Oral Disintegrating Strips

- Non-binding term sheet outlines the exclusive distribution of Pasture’s proprietary Oral Disintegrating Strips (sildenafil 50mg) (“**ODS**”), also known as HART-S.
- Reflects the next step in commercialising Pasture’s ODS drug delivery system, with a formal distribution agreement expected to follow.
- Marks a strategic milestone in Pasture’s long-term vision to develop and expand innovative and accessible drug delivery systems across the region.

Singapore, 20 May 2025 – Pasture Holdings Ltd. (“**Pasture**” or the “**Company**”, and together with its subsidiaries, the “**Group**”), a global pharmaceutical products and medical supplies and devices company, together with its appointed Thailand market authorisation holder, Biogenetech Co., Ltd., is pleased to announce the signing of a non-binding term sheet with the Government Pharmaceutical Organization of Thailand (“**GPO**”). The term sheet sets out the terms of an exclusive distribution agreement for Pasture’s proprietary Oral Disintegrating Strips drug delivery system containing the active ingredient sildenafil in Thailand.

The term sheet details key commercial terms under discussion and is expected to lead to a formal distribution agreement positioning GPO as the exclusive distributor of ODS (sildenafil 50mg) in Thailand. The term sheet reflects the commercial viability of Pasture’s proprietary ODS platform, marking a definitive step in its long-term strategy to scale innovative and accessible drug delivery systems across the region.

“Our ODS was a cornerstone of our growth story during the IPO,” said Lloyd Soong, Executive Chairman and CEO of Pasture Holdings Ltd. “While timelines have evolved, the term sheet demonstrates our strategic focus towards the key drivers we promised our investors. We continue to prioritize sustainable growth through effective and thoughtful healthcare solutions. This strategic step with GPO Thailand opens new revenue opportunities and strengthens our regional presence.”

Buildings Towards Innovative Healthcare Solutions

The term sheet reinforces Pasture’s long-term vision to improve drug administration and patient experiences through discreet, fast-acting, and accessible solutions. Drug delivery systems are at the core of Pasture’s innovation strategy to deliver scalable, adaptable care solutions that respond to evolving market needs.

The signing of this term sheet reflects meaningful intent and alignment between both parties after a prolonged period of negotiation and due diligence. Following the promising results of a clinical trial conducted on HART-S, this term sheet is the next visible step in advancing Pasture’s ODS products toward commercial availability.

About HART-S (sildenafil 50mg)

HART-S is Pasture Holdings' proprietary oral disintegrating strip (ODS) formulation containing sildenafil 50mg, developed for the treatment of erectile dysfunction. Designed to offer a discreet, fast-acting alternative to conventional tablets, HART-S dissolves quickly in the mouth without the need for water. In a prospective, randomized clinical trial conducted independently by Thailand's Government Pharmaceutical Organization (GPO) under the Ministry of Public Health, HART-S was shown to be equally effective and safe as traditional tablets, with a faster onset of action and enhanced patient convenience. The study was published in 2021 by Elsevier Inc. on behalf of the International Society for Sexual Medicine.

To read the full study, visit: <https://doi.org/10.1016/j.esxm.2021.100453>

About Pasture Holdings Ltd.

Pasture is a Singapore-based, global pharmaceutical products and medical supplies and devices company. Having supplied to over 50 countries, the Group has a comprehensive portfolio of over 1,000 third-party pharmaceutical products and over 1,200 medical supplies and devices. In addition, Pasture develops, markets and sells its own proprietary range of masks under the *Pasture Masks* brand and, as part of its pharmaceutical wholesale and drop-shipment business, specialises in cold-chain management services relating to temperature-sensitive pharmaceutical products. The Group is also involved in other new complementary products and services such as *HART-S ODS*, its own range of oral disintegrating strips and *furlife*, a mobile application and website for pet health services. Pasture continues to prioritize accessible healthcare by remaining agile, purpose-driven, and responsive to evolving market needs.

For more information, please visit <https://pasturegroup.com/>

Issued for and on behalf of Pasture Holdings Ltd.

By Financial PR

For more information, please contact

Kamal SAMUEL / Rishika TIWARI

E-mail: kamal@financialpr.com.sg / rishika@financialpr.com.sg

Tel: 6438 2990

Pasture Holdings Ltd. (the "**Company**") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") on 9 June 2023. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**").

This press release and its contents have been reviewed by the Sponsor. It has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release. The contact person for the Sponsor is Mr. Shervyn Essex, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.
